These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34478672)

  • 1. Sintilimab plus IBI305 for hepatocellular carcinoma - Author's reply.
    Fan J
    Lancet Oncol; 2021 Sep; 22(9):e388. PubMed ID: 34478672
    [No Abstract]   [Full Text] [Related]  

  • 2. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sintilimab plus IBI305 for hepatocellular carcinoma.
    Cheng L; Xiao H
    Lancet Oncol; 2021 Sep; 22(9):e387. PubMed ID: 34478671
    [No Abstract]   [Full Text] [Related]  

  • 4. Sintilimab plus IBI305 for hepatocellular carcinoma.
    Bomze D; Meirson T; Azoulay D
    Lancet Oncol; 2021 Sep; 22(9):e386. PubMed ID: 34478670
    [No Abstract]   [Full Text] [Related]  

  • 5. Complete response to the combination of sintilimab and IBI305 for a patient with HBV-associated hepatocellular carcinoma with multiple lung metastasis.
    Duan X; Zhang H; Zhou L; Jiang B; Mao X
    Dig Liver Dis; 2020 Jul; 52(7):794-796. PubMed ID: 32386943
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter to the editor: Atezolizumab plus bevacizumab for hepatocellular carcinoma in the real world.
    Zhang J; Fang J; Xun Z; Xu Y; Lu X; Zhao H
    Hepatology; 2022 Oct; 76(4):E84-E85. PubMed ID: 35604038
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma.
    Iwamoto H; Shimose S; Niizeki T; Koga H; Torimura T
    Clin Mol Hepatol; 2022 Jul; 28(3):575-579. PubMed ID: 35443321
    [No Abstract]   [Full Text] [Related]  

  • 8. Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib.
    Zhang Z; Zhou Y; Hu K; Li Z; Wang Z; Huang Y
    Dig Liver Dis; 2019 Oct; 51(10):1488-1490. PubMed ID: 31401020
    [No Abstract]   [Full Text] [Related]  

  • 9. Pursuing efficacious systemic therapy for hepatocellular carcinoma.
    Cheng AL
    Nat Rev Gastroenterol Hepatol; 2021 Feb; 18(2):95-96. PubMed ID: 33408363
    [No Abstract]   [Full Text] [Related]  

  • 10. Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.
    Chen SC; Chao Y; Yang MH
    Am J Gastroenterol; 2017 Apr; 112(4):659-660. PubMed ID: 28381841
    [No Abstract]   [Full Text] [Related]  

  • 11. Cetuximab for resectable colorectal liver metastasis: new EPOC trial--author's reply.
    Primrose JN
    Lancet Oncol; 2014 Jul; 15(8):e306. PubMed ID: 24988933
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients.
    Zhang W; Gong C; Peng X; Bi X; Sun Y; Zhou J; Wu F; Zeng H; Wang Y; Zhou H; Zhao H; Cai J; Zhou A
    Clin Cancer Res; 2022 Aug; 28(16):3499-3508. PubMed ID: 35275208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver dysfunction of Atezolizumab + Bevacizumab -a matter of life or death.
    Obi S; Omata M
    Liver Int; 2021 Jul; 41(7):1702-1703. PubMed ID: 34049421
    [No Abstract]   [Full Text] [Related]  

  • 14. [New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
    Minot-This MS; Edeline J
    Bull Cancer; 2021 Feb; 108(2):139-140. PubMed ID: 33546873
    [No Abstract]   [Full Text] [Related]  

  • 15. Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report.
    Fu L; Chen P; Wang S; Liu W; Chen Z; Chen H; Fu Z
    Anticancer Drugs; 2022 Jan; 33(1):e741-e746. PubMed ID: 34338239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fasciitis induced by sintilimab in a patient with recurrent hepatocellular carcinoma.
    Ning C; Zhang X; Yang X; Zhao H; Wang H
    Eur J Cancer; 2021 Sep; 155():296-298. PubMed ID: 34364744
    [No Abstract]   [Full Text] [Related]  

  • 17. Is ageing a problematic hurdle to the efficacy of first-line atezolizumab plus bevacizumab in hepatocellular carcinoma?
    An J; Shim JH
    Liver Int; 2022 Nov; 42(11):2352-2353. PubMed ID: 36162086
    [No Abstract]   [Full Text] [Related]  

  • 18. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L; Zou X; Chen Y; Bai X; Liang T
    Front Immunol; 2020; 11():2076. PubMed ID: 32973816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
    Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
    JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.